Dec 06, 07
|
| NEW STORY |
| 08:30 ET |
Nabi Biopharmaceuticals Announces Share Repurchase Program
|
|
Dec 04, 07
|
| 12:12 ET |
Nabi Biopharmaceuticals Completes Sale of Nabi Biologics to Biotest AG
|
|
Nov 28, 07
|
| 13:00 ET |
Nabi Biopharmaceuticals to Present at the BMO Capital Markets Focus on Healthcare Conference
|
|
Nov 08, 07
|
| 16:45 ET |
Nabi Biopharmaceuticals' Stockholders Approve Asset Sale
|
|
| 16:05 ET |
Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting
|
|
Nov 07, 07
|
| 10:30 ET |
Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
|
|
Oct 30, 07
|
| 13:30 ET |
RiskMetrics Group (ISS) and Glass Lewis & Co. Support Nabi Biopharmaceuticals' Proposed Asset Sale
|
|
Oct 24, 07
|
| 11:00 ET |
Nabi Biopharmaceuticals Announces Mailing of Definitive Proxy Statement and Release Date of Third Quarter 2007 Financial Results
|
|
Sep 11, 07
|
| 06:00 ET |
Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
|
|
Sep 05, 07
|
| 16:05 ET |
Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
|
|
Aug 23, 07
|
| 16:45 ET |
Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
|
|
Aug 01, 07
|
| 16:05 ET |
Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
|
|
Jul 20, 07
|
| 16:30 ET |
Nabi Biopharmaceuticals Announces Creation of Pharmaceuticals Business Unit
|
|
Jul 18, 07
|
| 16:30 ET |
Nabi Biopharmaceuticals to Announce Second Quarter Financial Results on August 1, 2007
|
|
Jul 12, 07
|
| 17:44 ET |
Nabi Biopharmaceuticals Appoints Matthew W. Kalnik, Ph.D., as Vice President, Business Development and Project Management
|
|
Jun 18, 07
|
| 09:22 ET |
Nabi Biopharmaceuticals Announces Creation of Biologics Business Unit & Provides Strategic Updates
|
|
May 30, 07
|
| 16:30 ET |
Nabi Biopharmaceuticals Announces Participation in Phacilitate Vaccine Forum Munich 2007
|
|
May 18, 07
|
| 16:15 ET |
Nabi Biopharmaceuticals Announces Results of 2007 Annual Meeting of Stockholders
|
|
May 02, 07
|
| 16:09 ET |
Nabi Biopharmaceuticals Announces First Quarter 2007 Financial Results
|
|
| 09:16 ET |
Nabi Biopharmaceuticals Announces Positive Results of Phase IIb Trial of NicVAX
|
|
Apr 19, 07
|
| 16:30 ET |
Nabi Biopharmaceuticals Announces Agreement to Sell Aloprim(TM)
|
|
Mar 15, 07
|
| 18:16 ET |
Nabi Biopharmaceuticals Files Form 10-K and Corrects Financial Tables
|
|
Mar 13, 07
|
| 15:41 ET |
Nabi Biopharmaceuticals to Present at the Lehman Brothers Tenth Annual Global Healthcare Conference
|
|
Mar 12, 07
|
| 16:01 ET |
Nabi Biopharmaceuticals Announces Fourth Quarter and Full-Year 2006 Financial Results
|
|
Feb 21, 07
|
| 14:24 ET |
Nabi Biopharmaceuticals to Announce 2006 Fourth Quarter and Year-End Financial Results on March 12, 2007
|
|
Feb 16, 07
|
| 17:03 ET |
Nabi Biopharmaceuticals' Dr. Henrik Rasmussen Resigns as Company's Senior Vice President, Clinical, Medical and Regulatory Affairs
|
|
Feb 15, 07
|
| 17:55 ET |
Nabi Biopharmaceuticals Announces Resignation of Thomas McLain as CEO and Appointment of Leslie Hudson as Interim CEO
|
|
Feb 07, 07
|
| 13:59 ET |
Nabi Biopharmaceuticals to Present at the BIO CEO and Investor Conference 2007
|
|
Feb 06, 07
|
| 14:22 ET |
Nabi Biopharmaceuticals to Announce 2006 Fourth Quarter and Year-End Financial Results on February 28, 2007
|
|
Jan 16, 07
|
| 08:00 ET |
Nabi Biopharmaceuticals Announces Initiation of Civacir(R) Phase II 'Proof-of- Concept' Clinical Trial
|
|
Nov 14, 06
|
| 19:30 ET |
Nabi Biopharmaceuticals Announces Satisfactory Completion of Voluntary Review of Equity Grant Programs; Third Quarter 2006 10-Q Filed within the Five-Day Extension Period
|
|
| 16:01 ET |
Nabi Biopharmaceuticals Closes Sale of PhosLo(R) to Fresenius Medical Care
|
|
Nov 13, 06
|
| 08:49 ET |
Nabi Biopharmaceuticals and Third Point Reach Agreement
|
|
Oct 31, 06
|
| 09:33 ET |
Nabi Biopharmaceuticals Comments on Third Point's Filing
|
|
Oct 25, 06
|
| 16:06 ET |
Nabi Biopharmaceuticals Reports Third Quarter 2006 Revenue and Cash Flow Results
|
|
Oct 16, 06
|
| 10:00 ET |
Nabi Biopharmaceuticals Sends Letter to Shareholders
|
|
| 08:00 ET |
Nabi Biopharmaceuticals Announces Positive Results From PhosLo(R) EPICK Study
|
|
Oct 12, 06
|
| 07:05 ET |
Nabi Biopharmaceuticals Completes Enrollment in NicVAX Phase IIB 'Proof-of-Concept' Clinical Trial
|
|
| 01:00 ET |
Nabi Biopharmaceuticals Signs Definitive Agreement to Sell PhosLo(R) to Fresenius Medical Care
|
|
Oct 10, 06
|
| 16:30 ET |
Nabi Biopharmaceuticals to Announce Third Quarter 2006 Financial Results on October 25, 2006
|
|
Sep 27, 06
|
| 16:01 ET |
Nabi Biopharmaceuticals Board Authorizes Exploration of Strategic Alternatives to Further Enhance Shareholder Value
|
|
Aug 29, 06
|
| 12:38 ET |
Nabi Biopharmaceuticals Acquires Exclusive Rights to Novel Plasma Fractionation Technology from ProMetic Life Sciences
|
|
Jul 26, 06
|
| 16:01 ET |
Nabi Biopharmaceuticals Reports Second Quarter 2006 Results
|
|
Jul 19, 06
|
| 08:30 ET |
Nabi Biopharmaceuticals to Announce Second Quarter 2006 Financial Results on July 26, 2006
|
|
Jul 18, 06
|
| 08:37 ET |
Nabi Biopharmaceuticals Releases New Data which Demonstrate Superior Serum Phosphorus Control with PhosLo(R) (calcium acetate) over Sevelamer
|
|
Jul 13, 06
|
| 15:17 ET |
Nabi Biopharmaceuticals Receives Positive Opinion from FDA Blood Products Advisory Committee for Nabi-HB(TM) Intravenous
|
|
Jul 06, 06
|
| 11:44 ET |
Nabi Biopharmaceuticals Joins Russell Microcap(TM) Index
|
|
Jun 29, 06
|
| 08:35 ET |
Nabi Biopharmaceuticals Secures Agreement with Kedrion to Co-Develop and Commercialize Civacir(R) in Europe
|
|
Jun 12, 06
|
| 16:06 ET |
Nabi Biopharmaceuticals Names Jordan I. Siegel Chief Financial Officer
|
|
May 30, 06
|
| 16:51 ET |
Nabi Biopharmaceuticals Provides Regulatory Update on Hepatitis B Liver Transplant Programs
|
|
May 24, 06
|
| 16:34 ET |
Nabi Biopharmaceuticals Initiates Phase IIB "Proof-of-Concept" Study For NicVAX
|
|
| 08:30 ET |
Nabi Biopharmaceuticals Appoints Peter B. Davis, 30-Year Biotechnology Finance Executive, to its Board of Directors
|
|
May 12, 06
|
| 14:37 ET |
Nabi Biopharmaceuticals Announces Results of 2006 Annual Meeting of Stockholders
|
|
May 03, 06
|
| 16:01 ET |
Nabi Biopharmaceuticals to Present at the Bank of America Health Care Conference 2006
|
|
Apr 26, 06
|
| 16:01 ET |
Nabi Biopharmaceuticals Announces First Quarter 2006 Financial Results
|
|
| 08:30 ET |
Nabi Biopharmaceuticals Secures 'Supply and Contract Manufacturing' Agreement with Sanofi Pasteur for Anti-Rabies Product
|
|
Apr 17, 06
|
| 16:01 ET |
Nabi Biopharmaceuticals to Announce First Quarter 2006 Financial Results on April 26, 2006
|
|
Apr 03, 06
|
| 16:01 ET |
Nabi Biopharmaceuticals Acquires Exclusive North American Commercialization Rights to Phase III Antibody Product for Prevention and Treatment of Rejection Following Organ Transplantation
|
|
Mar 21, 06
|
| 16:34 ET |
Nabi Biopharmaceuticals Announces Completion of Outside Advisory Panel Assessment of Gram-Positive Program
|
|
Mar 09, 06
|
| 10:26 ET |
Nabi Biopharmaceuticals Announces U.S. Fast Track Designation for NicVAX(R)
|
|
Mar 03, 06
|
| 08:40 ET |
Nabi Biopharmaceuticals to Present at the Lehman Brothers Ninth Annual Global Healthcare Conference
|
|
Feb 23, 06
|
| 16:23 ET |
Nabi Biopharmaceuticals Announces Full Year And Fourth Quarter 2005 Financial Results
|
|
Feb 10, 06
|
| 11:33 ET |
Nabi Biopharmaceuticals to Present at the BIO CEO and Investor Conference 2006
|
|
Feb 07, 06
|
| 08:32 ET |
Nabi Biopharmaceuticals Announces Positive Phase I Results From Its S. epidermidis PS-1 and S. aureus Type 336 Vaccine Clinical Trials
|
|
Feb 06, 06
|
| 17:23 ET |
Nabi Biopharmaceuticals to Hold Conference Call to Provide Summary of its Various Pipeline Programs
|
|
Feb 01, 06
|
| 19:16 ET |
Nabi Biopharmaceuticals Announces U.S. Fast Track Designation for Civacir to Prevent Hepatitis C Re-infection in Liver Transplants
|
|
Jan 30, 06
|
| 17:18 ET |
Nabi Biopharmaceuticals' Mark L. Smith Resigns as Company's CFO, Effective on or Around March 1, 2006
|
|
Jan 26, 06
|
| 17:24 ET |
Nabi Biopharmaceuticals Names Thomas E. Rathjen Vice President of Investor Relations
|
|
Jan 25, 06
|
| 19:40 ET |
Nabi Biopharmaceuticals Provides Update on Strategic Direction of NicVAX(TM) Program
|
|
Jan 11, 06
|
| 13:43 ET |
Nabi Biopharmaceuticals to Announce 2005 Fourth Quarter and Year-End Financial Results on February 23, 2006
|
|
Dec 20, 05
|
| 16:30 ET |
Nabi Biopharmaceuticals Updates Progress of its Gram-Positive Infections Portfolio
|
|
Dec 19, 05
|
| 16:45 ET |
Nabi Biopharmaceuticals Updates European Commercialization Strategy
|
|
Nov 21, 05
|
| 12:25 ET |
Large Proportion of Patients on Renagel(R) Receive Calcium Supplementation to Avoid Abnormally Low Levels of Calcium in Their Blood
|
|
| 12:21 ET |
Large Proportion of Patients on Renagel(R) Receive Calcium Supplementation to Avoid Abnormally Low Levels of Calcium in their Blood
|
|
Nov 01, 05
|
| 08:09 ET |
Nabi Biopharmaceuticals Announces Results of StaphVAX(R) Confirmatory Phase III Clinical Trial
|
|
Oct 19, 05
|
| 16:04 ET |
Nabi Biopharmaceuticals Reports Third Quarter 2005 Results
|
|
Oct 17, 05
|
| 10:27 ET |
Nabi Biopharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Life Sciences Conference
|
|
Oct 12, 05
|
| 16:10 ET |
Nabi Biopharmaceuticals Announces Successful Results from StaphVAX(R) Consistency Lots Study
|
|
Oct 11, 05
|
| 16:05 ET |
Nabi Biopharmaceuticals Strengthens Patent Portfolio for Gram-Positive Franchise With Award of Patent for Staphylococcal Antigen and Vaccine
|
|
Oct 07, 05
|
| 18:30 ET |
Nabi Biopharmaceuticals Presents Data Showing Patients Treated with Altastaph Were Relieved of Fever and Bacteremia Sooner than the Placebo Group
|
|
Sep 29, 05
|
| 18:09 ET |
StaphVAX(R) Immunogenicity Study in Orthopedic Patients Meets Primary Endpoints of Safety and Immune Response
|
|
Sep 27, 05
|
| 08:32 ET |
Nabi Biopharmaceuticals Files Lawsuit for Infringement of its PhosLo(R) Gelcap Patent
|
|
Sep 26, 05
|
| 09:01 ET |
Nabi Biopharmaceuticals to Announce Third Quarter 2005 Financial Results On October 19, 2005
|
|
Sep 22, 05
|
| 08:01 ET |
Nabi Biopharmaceuticals Receives Favorable Opinion From the Committee on Orphan Medicinal Products for Altastaph(TM) in Europe
|
|
Sep 20, 05
|
| 07:50 ET |
Nabi Biopharmaceuticals Launches New Study to Evaluate StaphVAX(R)'s Ability to Provide Long-term Protection from S. aureus Infections in Chronic, High-Risk Patient Groups
|
|
Sep 12, 05
|
| 16:05 ET |
Nabi Biopharmaceuticals Receives NIDA Grant to Fund NicVAX(TM) Development
|
|
Sep 08, 05
|
| 08:30 ET |
Nabi Biopharmaceuticals Appoints Vice President of Sales and Marketing in Europe and Country Manager, Nabi Biopharmaceuticals UK Limited
|
|
Sep 07, 05
|
| 16:17 ET |
Nabi Biopharmaceuticals Appoints Joseph Johnson, Senior Vice President
|
|
Sep 06, 05
|
| 17:32 ET |
Nabi Biopharmaceuticals to Present at the Bear Stearns 18th Annual Healthcare Conference
|
|
Sep 02, 05
|
| 08:14 ET |
Nabi Biopharmaceuticals to Present at the Thomas Weisel Partners 'Healthcare Tailwinds 2005' Conference
|
|
Aug 22, 05
|
| 16:37 ET |
Nabi Biopharmaceuticals Appoints Leslie Hudson, Ph.D., to its Board of Directors
|
|
Aug 03, 05
|
| 16:29 ET |
Nabi Biopharmaceuticals' New PhosLo Share Program(TM) Expands Access to Broader Population of End-Stage Renal (Kidney) Disease Patients On Hemodialysis
|
|
Jul 21, 05
|
| 08:24 ET |
Nabi Biopharmaceuticals Initiates Phase I Study of Staphylococcus aureus Type 336 Vaccine
|
|
Jul 20, 05
|
| 08:30 ET |
Nabi Biopharmaceuticals Announces Completion of NicVAX(TM) Phase II Clinical Trial Enrollment
|
|
Jul 19, 05
|
| 16:12 ET |
Nabi Biopharmaceuticals Reports Second Quarter 2005 Results
|
|
Jul 12, 05
|
| 09:19 ET |
StaphVAX(R) Immunogenicity Study in Cardiac Patients Meets Primary Endpoints of Safety and Immune Response
|
|
Jul 06, 05
|
| 08:31 ET |
Nabi Biopharmaceuticals to Announce Second Quarter 2005 Financial Results on July 19, 2005
|
|
Jun 29, 05
|
| 11:03 ET |
Thomas H. McLain Appointed to the Biotechnology Industry Organization's Board of Directors
|
|
Jun 27, 05
|
| 16:23 ET |
Nabi Biopharmaceuticals Names Constance C. Bienfait Vice President of Investor Relations
|
|
Jun 23, 05
|
| 14:47 ET |
Nabi Biopharmaceuticals to Present at the Bear Stearns Boston Biotech Confab
|
|
Jun 22, 05
|
| 16:05 ET |
Nabi Biopharmaceuticals Gains Orphan Medicinal Product Designation For Civacir(TM) in Europe
|
|
Jun 14, 05
|
| 09:19 ET |
Nabi Biopharmaceuticals Provides Update on Progress of Bacterial Infections Programs; Preview to Investor/Analyst Day
|
|
Jun 13, 05
|
| 15:34 ET |
Nabi Biopharmaceuticals to Host Investor/Analyst Day in New York City
|
|
Jun 02, 05
|
| 08:31 ET |
Nabi Biopharmaceuticals Dedicates Its New Vaccine Manufacturing Facility
|
 |
May 25, 05
|
| 17:11 ET |
Nabi Biopharmaceuticals Initiates S. Epidermidis Vaccine Phase I Study
|
|
May 19, 05
|
| 15:23 ET |
Nabi Biopharmaceuticals Names Stephan E. Lawton Vice President of Government Relations
|
|
May 18, 05
|
| 10:11 ET |
Nabi Biopharmaceuticals Initiates StaphVAX(R) Bridging and Consistency Lot Studies
|
|
May 17, 05
|
| 16:31 ET |
Nabi Biopharmaceuticals to Present at Three May Conferences
|
|
| 08:30 ET |
Nabi Biopharmaceuticals Initiates StaphVAX(R) Immunogenicity Study in Orthopedic Surgery Patients in the United Kingdom
|
|
May 10, 05
|
| 16:01 ET |
Nabi Biopharmaceuticals Initiates PhosLo(R) Epick Study in Chronic Kidney Disease Patients
|
|
| 08:53 ET |
Nabi Biopharmaceuticals to Present at the BioVenture East Conference
|
|
May 06, 05
|
| 12:42 ET |
Nabi Biopharmaceuticals to Present at the Bear Stearns 7th Annual London Healthcare Conference
|
|
Apr 29, 05
|
| 16:01 ET |
Nabi Biopharmaceuticals to Present at the Stanford Washington Research Group's Multi-Track 2005 Institutional Policy Conference
|
|
| 12:05 ET |
Nabi Biopharmaceuticals to Present at the Morgan Stanley Third Annual Global Healthcare Unplugged Conference
|
|
Apr 25, 05
|
| 15:30 ET |
Nabi Biopharmaceuticals to Present at the 5th Annual Fortis Bank Biotechnology Conference
|
|
| 09:20 ET |
Nabi Biopharmaceuticals Opens European Headquarters in Ireland
|
|
Apr 20, 05
|
| 16:11 ET |
Nabi Biopharmaceuticals Reports First Quarter 2005 Results
|
|
Apr 15, 05
|
| 14:27 ET |
Nabi Biopharmaceuticals to Present at White Mountain Capital's Third Annual Biotechnology Conference
|
|
Apr 14, 05
|
| 08:12 ET |
Nabi Biopharmaceuticals Announces Private Sale of $100 Million of 2.875% Convertible Senior Notes Due 2025
|
|
Apr 13, 05
|
| 14:42 ET |
Nabi Biopharmaceuticals to Announce First Quarter 2005 Financial Results on April 20, 2005
|
|
Apr 11, 05
|
| 16:30 ET |
Nabi Biopharmaceuticals Announces Proposed Private Offering of Convertible Senior Notes
|
|
Apr 05, 05
|
| 17:41 ET |
Nabi Biopharmaceuticals Updates Its 2005 Revenue Guidance
|
|
Mar 24, 05
|
| 17:00 ET |
Nabi Biopharmaceuticals to Present at the Lehman Brothers Eighth Annual Global Healthcare Conference
|
|
| 17:00 ET |
Nabi Biopharmaceuticals to Present at the Smith Barney Citigroup 2005 Healthcare Conference
|
|
Mar 10, 05
|
| 16:05 ET |
Nabi Biopharmaceuticals Restates Amortization of Manufacturing Right Intangible Asset in Its 2003 and 2002 Financial Statements
|
|
Feb 25, 05
|
| 17:07 ET |
Nabi Biopharmaceuticals to Present at the Leerink Swann & Company/MEDACorp Inaugural Health Care Conference
|
|
Feb 18, 05
|
| 09:15 ET |
Nabi Biopharmaceuticals to Present at the BIO CEO and Investor Conference 2005
|
|
Feb 15, 05
|
| 16:21 ET |
Nabi Biopharmaceuticals Reports Year-End and Fourth Quarter 2004 Results
|
|
Jan 26, 05
|
| 16:54 ET |
Nabi Biopharmaceuticals' StaphVAX(R) MAA Accepted for Review by the European Medicines Evaluation Agency
|
|
Jan 18, 05
|
| 09:30 ET |
Nabi Biopharmaceuticals to Present at the Piper Jaffray Health Care Conference
|
|
Jan 13, 05
|
| 08:56 ET |
Nabi Biopharmaceuticals to Announce Fourth Quarter and Year-End Financial Results for 2004 on February 15, 2005
|
|
Jan 10, 05
|
| 09:00 ET |
Nabi Biopharmaceuticals Reports Encouraging Phase I/II Altastaph(TM) Results in Adults
|
|
Jan 06, 05
|
| 17:22 ET |
Nabi Biopharmaceuticals Announces Initiation of New StaphVAX(R) Immunogenicity Study in Orthopedic Surgery Patients
|
|
Dec 21, 04
|
| 09:23 ET |
Nabi Biopharmaceuticals Files for European Regulatory Approval for StaphVAX(R) to Prevent S. Aureus Infections in End-Stage Renal Disease Patients
|
|
Dec 20, 04
|
| 15:18 ET |
Nabi Biopharmaceuticals Names H. Le Roux Jooste Senior Vice President, Global Sales and Marketing
|
|
Dec 14, 04
|
| 13:44 ET |
Nabi Biopharmaceuticals to Present at the Wachovia Securities Ten for '05 Biotechnology Conference
|
|
Dec 08, 04
|
| 16:04 ET |
Nabi Biopharmaceuticals Continues to Make Important Progress With StaphVAX(R) Development Program
|
|
Dec 07, 04
|
| 15:28 ET |
Nabi Biopharmaceuticals Announces Filing of Shelf Registration
|
|
Dec 06, 04
|
| 11:46 ET |
Nabi Biopharmaceuticals to Present at the Harris Nesbitt 'Focus on Healthcare' Conference
|
|
Nov 29, 04
|
| 10:03 ET |
Nabi Biopharmaceuticals Names Pamela Joy Barton, Ph.D. as Vice President, Business Development
|
|
Nov 17, 04
|
| 16:05 ET |
Nabi Biopharmaceuticals Announces Altastaph(TM) Phase II Trial Results in Neonates
|
|
Nov 10, 04
|
| 13:36 ET |
New Study Demonstrates the Clinical and Economic Challenges of Staphylococcus Aureus Infections
|
|
Nov 04, 04
|
| 16:45 ET |
Nabi Biopharmaceuticals Files PhosLo(R) Common Technical Document in Europe
|
|
Oct 25, 04
|
| 08:45 ET |
Nabi Biopharmaceuticals to Present at the C.E. Unterberg Towbin Specialty Pharmaceutical Conference
|
|
Oct 21, 04
|
| 10:11 ET |
Nabi Biopharmaceuticals' Thomas H. McLain Elected as Chairman of BioFlorida
|
|
Oct 19, 04
|
| 16:08 ET |
Nabi Biopharmaceuticals Reports Strong Cash Flow From Operations for the Third Quarter of 2004
|
|
Oct 14, 04
|
| 08:45 ET |
Nabi Biopharmaceuticals Awarded European Patent for NicVAX(TM)
|
|
Oct 12, 04
|
| 16:15 ET |
Nabi Biopharmaceuticals' StaphVAX(R) Receives Fast Track Designation in the United States
|
|
Oct 11, 04
|
| 08:47 ET |
Nabi Biopharmaceuticals to Announce Third Quarter 2004 Financial Results on October 19, 2004
|
|
Oct 05, 04
|
| 07:33 ET |
Nabi Biopharmaceuticals Announces PhosLo(R) CARE 2 Study
|
|
Sep 29, 04
|
| 16:44 ET |
Nabi Biopharmaceuticals to Host Investor/Analyst Day in New York City
|
|
Sep 28, 04
|
| 07:01 ET |
Nabi Biopharmaceuticals Announces Positive Phase II Results With NicVAX(TM) for Smoking Cessation
|
|
Sep 24, 04
|
| 12:43 ET |
Nabi Biopharmaceuticals to Present at the UBS Global Life Sciences Conference
|
|
Sep 09, 04
|
| 17:28 ET |
Nabi Biopharmaceuticals to Present at the Bear Stearns 17th Annual Healthcare Conference
|
|
Aug 17, 04
|
| 08:56 ET |
Nabi Biopharmaceuticals Completes Patient Enrollment for StaphVAX(R) Phase III Trial and Completes Consistency Lot Manufacturing
|
|
Aug 10, 04
|
| 12:26 ET |
Nabi Biopharmaceuticals Awarded Patent on Enterococcus Antigens and Vaccines
|
|
Jul 20, 04
|
| 16:09 ET |
Nabi Biopharmaceuticals Reports Record Biopharmaceutical Sales in the Second Quarter of 2004
|
|
Jul 19, 04
|
| 08:45 ET |
Nabi Biopharmaceuticals Announces New Date for Second Quarter 2004 Financial Results
|
|
Jul 16, 04
|
| 12:45 ET |
Nabi Biopharmaceuticals Announces New Date for Second Quarter 2004 Financial Results
|
|
Jul 12, 04
|
| 08:40 ET |
Nabi Biopharmaceuticals Begins Internal Expansion of its Manufacturing Capacity for Company's Pipeline Vaccine Products
|
|
Jul 01, 04
|
| 08:27 ET |
Nabi Biopharmaceuticals to Announce Second Quarter 2004 Financial Results on July 21, 2004
|
|
Jun 30, 04
|
| 11:40 ET |
Nabi Biopharmaceuticals Acquires Full Rights to Aloprim(TM)
|
|
Jun 24, 04
|
| 15:20 ET |
Nabi Biopharmaceuticals Advances European Commercialization Strategy With Filing for Nabi-HB(R) Intravenous
|
|
Jun 22, 04
|
| 10:29 ET |
Nabi Biopharmaceuticals Takes Steps to Expand Market Potential for StaphVAX(R) Beyond ESRD Patient Population
|
|
Jun 21, 04
|
| 13:43 ET |
Nabi Biopharmaceuticals to Present at the Wachovia Securities Fourteenth Annual Nantucket Conference
|
|
Jun 15, 04
|
| 09:17 ET |
Nabi Biopharmaceuticals to Present at the Needham & Co. Third Annual Biotechnology Conference
|
|
Jun 10, 04
|
| 16:57 ET |
Nabi Biopharmaceuticals Advances PhosLo(R) Commercial Strategy With Initiation of PRECISE Trial
|
|
Jun 07, 04
|
| 09:25 ET |
Nabi Biopharmaceuticals to Participate in the BIO 2004 Annual International Convention in San Francisco
|
|
May 26, 04
|
| 08:53 ET |
Nabi Biopharmaceuticals to Host Investor/Analyst Day in New York City
|
|
May 18, 04
|
| 11:36 ET |
Nabi Biopharmaceuticals to Present at Banc of America Securities Health Care Conference 2004
|
|
| 10:51 ET |
Nabi Biopharmaceuticals Names Richard G. Clark, Senior Vice President, Administration and Chief Administrative Officer
|
|
| 09:50 ET |
Nabi Biopharmaceuticals Names Thomas H. McLain as Chairman of the Board of Directors
|
|
May 05, 04
|
| 09:54 ET |
Nabi Biopharmaceuticals to Present at Cambrex Corporation Annual Analyst Meeting
|
|
Apr 21, 04
|
| 16:12 ET |
Nabi Biopharmaceuticals Reports Financial Results For The First Quarter Of 2004
|
|
Apr 20, 04
|
| 11:39 ET |
Nabi Biopharmaceuticals to Present at the White Mountain Capital Second Annual Biotechnology Conference
|
|
Apr 19, 04
|
| 09:27 ET |
Study Published in Kidney International Supports Nabi's PhosLo(R) as Treatment of Choice for Hemodialysis Patients
|
|
Apr 06, 04
|
| 11:24 ET |
Nabi Biopharmaceuticals to Announce First Quarter 2004 Financial Results on April 21, 2004
|
|
Mar 31, 04
|
| 11:22 ET |
Nabi Biopharmaceuticals to Present at the Thomson Financial and Biocentury 11th Anniversary of 'Future Leaders in the Biotech Industry' Conference
|
|
Mar 15, 04
|
| 12:31 ET |
Nabi Biopharmaceuticals to Host Meeting on Innovations in Staph aureus Prevention and Treatment
|
|
Mar 09, 04
|
| 09:14 ET |
Nabi Biopharmaceuticals Signs Agreement with Novation LLC to Supply Novaplus(R) Nabi-HB(R)
|
|
Mar 03, 04
|
| 11:11 ET |
Nabi Biopharmaceuticals To Present At Lehman Brothers Seventh Annual Global Healthcare Conference
|
|
| 08:46 ET |
Nabi Biopharmaceuticals' Altastaph(TM) Receives FDA Fast Track Designation
|
|
Feb 25, 04
|
| 08:54 ET |
Nabi Biopharmaceuticals Announces Encouraging Results From NicVAX(TM) Phase I/II Clinical Trial in Smokers and Non-smokers
|
|
Feb 23, 04
|
| 09:14 ET |
Civacir(TM) Phase I/II Trial in Hepatitis C Liver Transplant Patients Completed, Preliminary Results Encouraging
|
|
| 09:01 ET |
Nabi Biopharmaceuticals To Present At BIO CEO & Investor Conference
|
|
Feb 20, 04
|
| 16:57 ET |
Nabi Biopharmaceuticals To Present At BIO CEO & Investor Conference
|
|
Feb 18, 04
|
| 16:10 ET |
Nabi Biopharmaceuticals Reports Year-End And Fourth Quarter 2003 Results
|
|
Feb 11, 04
|
| 08:34 ET |
Nabi Biopharmaceuticals Receives FDA Orphan Drug Designation for Altastaph(TM)
|
|
Feb 06, 04
|
| 09:25 ET |
Nabi Biopharmaceuticals Signs International Distribution Agreement for Nabi-HB(R)
|
|
Jan 21, 04
|
| 09:26 ET |
Nabi Biopharmaceuticals To Present At US Bancorp Piper Jaffray Healthcare Conference
|
|
Jan 20, 04
|
| 11:26 ET |
Nabi Biopharmaceuticals to Announce Fourth Quarter and Year-End Financial Results for 2003 on February 18, 2004
|
|
Dec 29, 03
|
| 12:11 ET |
Nabi Biopharmaceuticals Completes Common Stock Offering, Underwriters Exercise Overallotment Option
|
|
Dec 18, 03
|
| 09:25 ET |
Nabi Biopharmaceuticals Announces Pricing of Public Offering of 8,500,000 Shares of Common Stock at $10.00 Per Share
|
|
Dec 10, 03
|
| 09:30 ET |
Nabi Biopharmaceuticals Provides Update on StaphVAX(R) Development Program
|
|
Nov 26, 03
|
| 16:10 ET |
Nabi Biopharmaceuticals Files Registration Statement For Public Offering
|
|
Nov 14, 03
|
| 13:40 ET |
Data Presented at the 36th Annual American Society of Nephrology Meeting Continues to Support PhosLo(R) for First-line Treatment for Hyperphosphatemia in End-Stage Renal Disease Patients
|
|
| 09:10 ET |
Nabi Biopharmaceuticals Added to NASDAQ Biotechnology Index
|
|
| 09:02 ET |
Data Presented at the 36th Annual American Society of Nephrology Meeting Continues to Support PhosLo(R) for First-line Treatment for Hyperphosphatemia in End-Stage Renal Disease Patients
|
|
Oct 22, 03
|
| 16:15 ET |
Nabi Biopharmaceuticals Reports Financial Results For The Third Quarter Of 2003
|
|
Oct 15, 03
|
| 09:43 ET |
National Kidney Foundation K/DOQI Guidelines Help Define Use of Phosphate Binders Such as PhosLo(R) in Patients on Hemodialysis
|
|
Oct 09, 03
|
| 16:38 ET |
Nabi Biopharmaceuticals Accelerates Commercialization Plans for StaphVAX(R)
|
|
Oct 07, 03
|
| 12:41 ET |
Nabi Biopharmaceuticals Provides Guidance on PhosLo(R) Revenues
|
|
Sep 30, 03
|
| 08:45 ET |
Nabi Biopharmaceuticals to Announce Third Quarter 2003 Financial Results on October 22, 2003
|
|
Sep 29, 03
|
| 09:05 ET |
Nabi Biopharmaceuticals Initiates StaphVAX(R) Confirmatory Phase III Trial Ahead of Schedule
|
|
Sep 17, 03
|
| 11:34 ET |
Staph aureus Blood Stream Infection in End Stage Kidney Disease Associated With Substantial Illness and Increased Healthcare Costs
|
|
Sep 15, 03
|
| 08:28 ET |
Nabi Biopharmaceuticals to Present at UBS Global Life Sciences Conference
|
|
Sep 08, 03
|
| 10:47 ET |
Nabi Biopharmaceuticals Successfully Completes StaphVAX(R) Immunogenicity Study, Confirmatory Phase III Trial On Track
|
|
Aug 28, 03
|
| 08:49 ET |
Nabi Biopharmaceuticals Submits Additional Data On Nabi-HB(R) Intravenous Biological License Application
|
|
Aug 27, 03
|
| 08:39 ET |
Nabi Biopharmaceuticals' Tom McLain Named Best Technology Company CEO
|
|
Aug 05, 03
|
| 09:38 ET |
Nabi Biopharmaceuticals Initiates NicVAX(TM) Phase II Trial, Investigational Vaccine for the Prevention And Treatment of Nicotine Addiction
|
|
| 09:22 ET |
Nabi Biopharmaceuticals Completes PhosLo(R) Acquisition
|
|
Jul 29, 03
|
| 11:31 ET |
Nabi Biopharmaceuticals Initiates Altastaph(TM) Phase II Clinical Trial In Low Birth Weight Neonates
|
|
Jul 23, 03
|
| 16:11 ET |
Nabi Biopharmaceuticals Reports Second Quarter Net Loss In Line With Expectations
|
|
Jul 14, 03
|
| 08:59 ET |
Nabi Biopharmaceuticals Announces $32.9 Million Private Placement of Common Stock
|
|
Jul 07, 03
|
| 08:26 ET |
Nabi Biopharmaceuticals to Announce Second Quarter 2003 Financial Results on July 23, 2003
|
|
Jun 23, 03
|
| 16:05 ET |
Nabi Biopharmaceuticals Acquires Worldwide Rights To PhosLo(R) From Braintree Laboratories, Inc.
|
|
Jun 20, 03
|
| 15:01 ET |
Nabi Biopharmaceuticals Names Thomas H. McLain as Chief Executive Officer
|
|
| 14:56 ET |
Nabi Biopharmaceuticals' David J. Gury Named 2003 Entrepreneur of the Year, Announces Retirement as CEO
|
|
Jun 19, 03
|
| 08:18 ET |
Nabi Biopharmaceuticals Initiates StaphVAX(R) Immunogenicity Study
|
|
Jun 04, 03
|
| 10:33 ET |
Nabi Biopharmaceuticals Receives Complete Response From FDA On Nabi-HB(R) Intravenous, Hepatitis B Antibody Product Biological License Application (BLA)
|
|
May 28, 03
|
| 11:29 ET |
Nabi Biopharmaceuticals to Present at White Mountain Capital Biotechnology Conference
|
|
| 10:07 ET |
Nabi Biopharmaceuticals to Present at Needham & Company Second Annual Biotechnology Conference
|
|
Apr 23, 03
|
| 16:08 ET |
Nabi Biopharmaceuticals Reports 48% Increase In Biopharmaceutical Product Sales in First Quarter
|
|
Apr 14, 03
|
| 09:03 ET |
Nabi Biopharmaceuticals Licenses Its Staphylococcus aureus Whole Cell Vaccine Technology to Pharmacia Animal Health
|
|
Apr 02, 03
|
| 09:52 ET |
Nabi Biopharmaceuticals Names Raafat Fahim as Vice President, Vaccine Manufacturing Operations
|
|
Mar 27, 03
|
| 13:39 ET |
Nabi Biopharmaceuticals to Announce First Quarter 2003 Financial Results On April 23, 2003
|
|
| 12:01 ET |
Nabi Biopharmaceuticals Receives Second U.S. Patent Covering Staphylococcus Aureus Vaccine for Mastitis and Other Veterinary Uses
|
|
Feb 27, 03
|
| 10:36 ET |
Nabi Biopharmaceuticals to Present at 16th Annual Roth Capital Partners Growth Stock Conference
|
|
| 10:33 ET |
Nabi Biopharmaceuticals to Present at Lehman Brothers 6th Annual Global Healthcare Conference
|
|
Feb 25, 03
|
| 10:37 ET |
Nabi Biopharmaceuticals Names Henrik Rasmussen as Vice President, Clinical and Regulatory Affairs
|
|
Feb 20, 03
|
| 09:22 ET |
Florida Research Consortium Announces the Appointment of Jack Sullivan, Jr. as President and Chief Executive Officer
|
|
Feb 19, 03
|
| 16:07 ET |
Nabi Biopharmaceuticals Reports Record Biopharmaceutical Sales
|
|
| 08:15 ET |
Nabi Biopharmaceuticals Begins European Phase I/II Trial of NicVAX(TM), Investigational Vaccine for Prevention and Treatment of Nicotine Addiction
|
|
Feb 11, 03
|
| 09:45 ET |
Nabi Receives Second U.S. Patent Covering NicVAX(TM) For Treatment And Prevention of Nicotine Addiction
|
|
Jan 23, 03
|
| 08:59 ET |
FDA Accepts for Priority Review BLA Filed By Nabi Biopharmaceuticals for Liver Transplant Indication
|
|
Jan 21, 03
|
| 15:09 ET |
Nabi Biopharmaceuticals to Present at US Bancorp Piper Jaffray Health Care Conference
|
|
| 08:14 ET |
Nabi Biopharmaceuticals Announces Fourth Quarter 2002 Financial Results On February 19, 2003; Nabi Biopharmaceuticals Also Announces Date of Annual Meeting of Stockholders
|
|
Dec 05, 02
|
| 12:25 ET |
Nabi Biopharmaceuticals Receives Orphan Drug Designation for Civacir(TM), Investigational Hepatitis C Antibody Product in Clinical Trial
|
|
Nov 26, 02
|
| 12:32 ET |
Nabi Biopharmaceuticals Files BLA for Liver Transplant Indication for Nabi-HB(TM) Intravenous, Hepatitis B Antibody Product
|
|
Nov 25, 02
|
| 08:23 ET |
Nabi Biopharmaceuticals Names Daniel Greenleaf Senior Vice President, Operations
|
|
Nov 19, 02
|
| 07:51 ET |
Nabi Biopharmaceuticals Announces Thomas H. McLain Promoted to President
|
|
Oct 23, 02
|
| 16:06 ET |
Nabi Biopharmaceuticals Product Sales Growth Drives Positive Third Quarter Earnings Results; Third Quarter Results Exceed Expectations
|
|
Oct 22, 02
|
| 11:21 ET |
Nabi Biopharmaceuticals Announces Agreement With IDIS World Medicines To Distribute Nabi-HB(TM), Hepatitis B Antibody Product
|
|
Oct 17, 02
|
| 09:29 ET |
Nabi Biopharmaceuticals Expands Global Presence, Signs Two International Agreements to Distribute Nabi-HB(TM), Hepatitis B Antibody Product
|
|
Oct 03, 02
|
| 11:46 ET |
Nabi Biopharmaceuticals Reports Encouraging Preliminary Results Of NicVAX(TM) Clinical Trial
|
|
Sep 24, 02
|
| 12:50 ET |
Nabi Biopharmaceuticals to Present at UBS Warburg Global Life Sciences Conference
|
|
| 08:09 ET |
Nabi Biopharmaceuticals to Announce Third Quarter 2002 Financial Results on October 23, 2002
|
|
Sep 19, 02
|
| 15:27 ET |
Nabi Biopharmaceuticals' David J. Gury Named 2002 Businessperson of the Year
|
|